Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

76 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Valosin-containing protein phosphorylation at Ser784 in response to DNA damage.
Livingstone M, Ruan H, Weiner J, Clauser KR, Strack P, Jin S, Williams A, Greulich H, Gardner J, Venere M, Mochan TA, DiTullio RA Jr, Moravcevic K, Gorgoulis VG, Burkhardt A, Halazonetis TD. Livingstone M, et al. Among authors: greulich h. Cancer Res. 2005 Sep 1;65(17):7533-40. doi: 10.1158/0008-5472.CAN-04-3729. Cancer Res. 2005. PMID: 16140914
Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance.
Shimamura T, Li D, Ji H, Haringsma HJ, Liniker E, Borgman CL, Lowell AM, Minami Y, McNamara K, Perera SA, Zaghlul S, Thomas RK, Greulich H, Kobayashi S, Chirieac LR, Padera RF, Kubo S, Takahashi M, Tenen DG, Meyerson M, Wong KK, Shapiro GI. Shimamura T, et al. Among authors: greulich h. Cancer Res. 2008 Jul 15;68(14):5827-38. doi: 10.1158/0008-5472.CAN-07-5428. Cancer Res. 2008. PMID: 18632637 Free PMC article.
Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation.
Sos ML, Rode HB, Heynck S, Peifer M, Fischer F, Klüter S, Pawar VG, Reuter C, Heuckmann JM, Weiss J, Ruddigkeit L, Rabiller M, Koker M, Simard JR, Getlik M, Yuza Y, Chen TH, Greulich H, Thomas RK, Rauh D. Sos ML, et al. Among authors: greulich h. Cancer Res. 2010 Feb 1;70(3):868-74. doi: 10.1158/0008-5472.CAN-09-3106. Epub 2010 Jan 26. Cancer Res. 2010. PMID: 20103621 Free article.
Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272.
Shimamura T, Ji H, Minami Y, Thomas RK, Lowell AM, Shah K, Greulich H, Glatt KA, Meyerson M, Shapiro GI, Wong KK. Shimamura T, et al. Among authors: greulich h. Cancer Res. 2006 Jul 1;66(13):6487-91. doi: 10.1158/0008-5472.CAN-06-0971. Cancer Res. 2006. PMID: 16818618
Modeling genomic diversity and tumor dependency in malignant melanoma.
Lin WM, Baker AC, Beroukhim R, Winckler W, Feng W, Marmion JM, Laine E, Greulich H, Tseng H, Gates C, Hodi FS, Dranoff G, Sellers WR, Thomas RK, Meyerson M, Golub TR, Dummer R, Herlyn M, Getz G, Garraway LA. Lin WM, et al. Among authors: greulich h. Cancer Res. 2008 Feb 1;68(3):664-73. doi: 10.1158/0008-5472.CAN-07-2615. Cancer Res. 2008. PMID: 18245465 Free PMC article.
76 results